For the quarter ended December 2022, Regeneron (REGN) reported revenue of $3.41 billion, down 31.1% over the same period last year. EPS came in at $12.56, compared to $23.72 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $3.17 billion, representing a surprise of +7.84%. The company delivered an EPS surprise of +29.75%, with the consensus EPS estimate being $9.68.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company’s financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock’s price performance.
Here is how Regeneron performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Eylea (Aflibercept) – US: $1.50 billion versus the five-analyst average estimate of $1.69 billion. The reported number represents a year-over-year change of -3.3%.
- Revenue- Libtayo – US: $110 million versus the five-analyst average estimate of $103.86 million. The reported number represents a year-over-year change of +36.1%.
- Revenue- Eylea (Aflibercept) – ROW: $838.60 million versus the four-analyst average estimate of $864.85 million. The reported number represents a year-over-year change of -10.2%.
- Revenue- Praluent (alirocumab) – US: $35.50 million versus $31.17 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -11.3% change.
- Revenues- Net product sales: $1.70 billion versus the eight-analyst average estimate of $1.83 billion. The reported number represents a year-over-year change of -57.3%.
- Revenues- Other Revenue: $127.70 million compared to the $57.53 million average estimate based on seven analysts. The reported number represents a change of +48.1% year over year.
- Revenue-Collaboration: $1.59 billion versus $1.34 billion estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +78.3% change.
- Revenues- Collaboration revenue- Bayer: $355 million versus $349.35 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -4.7% change.
- Revenues- Collaboration revenue- Sanofi: $836 million compared to the $712.85 million average estimate based on five analysts. The reported number represents a change of +61.4% year over year.
- Revenues- Collaboration revenue- Roche: $396 million compared to the $245.50 million average estimate based on four analysts.
- Revenues- Eylea (Aflibercept) – Total: $2.34 billion versus the four-analyst average estimate of $2.55 billion.
- Revenues- Libtayo – Total: $168.80 million versus $151.25 million estimated by three analysts on average.
View all Key Company Metrics for Regeneron here>>>
Shares of Regeneron have returned +3.8% over the past month versus the Zacks S&P 500 composite’s +9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Just Released: Zacks Top 10 Stocks for 2023
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for 2023?
From inception in 2012 through November, the Zacks Top 10 Stocks portfolio has tripled the market, gaining an impressive +884.5% versus the S&P 500’s +287.4%. Our Director of Research has now combed through 4,000 companies covered by the Zacks Rank and handpicked the best 10 tickers to buy and hold in 2023. Don’t miss your chance to still be among the first to get in on these just-released stocks.
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Image and article originally from www.nasdaq.com. Read the original article here.